Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ET Company Participants David M. Altshuler - Executive VP & Chief S...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with ...

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

A new month has arrived. Investors now have a fresh opportunity to buy great stocks.

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising macroeconomic uncertainties, and geopolitical challenges, have weighed on ove...

Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the uncertain near-term economic outlook. Even with these issues, though, stocks a...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ET Company Participants Reshma Kewalramani - President & CEO Conference Cal...

Believe it or not, but we're not far away from being halfway through the year. Time flies when you're having fun -- and when you're not having fun, too.

The market's recent correction looks like a massive drop on a year-to-date chart. However, it will look far less daunting in a decade; that's what happens over the long run.

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Ver...